Organic cation transporter novel 1 (OCTN1): beyond an ergothioneine transporter Authors: Yumeng Guo, Kaijian Zhou, Jianguo Zhang, Zhimin Tao Published: 2026 ABSTRACT AbstractIn this review we comprehensively discuss organic cation transporter novel 1 (OCTN1), encoded by the SLC22A4 gene as a member in the solute carrier 22 (SLC22) family, which facilitates the cellular transport of diverse cationic and zwitterionic substrates. OCTN1 is highly expressed in many vital organs in humans, where it facilitates absorption and distribution of both endogenous compounds and therapeutic drugs. Among its substrates, ergothioneine (EGT) serves as the important antioxidant and anti-inflammatory molecule, underscoring the essential role of OCTN1 in cellular defense and inflammation control. Genetic polymorphisms in SLC22A4 significantly alter OCTN1 expression, substrate affinity, and drug pharmacokinetics, with strong associations to susceptibility and treatment outcomes in human diseases. Insights from knockout models revealed that OCTN1 deficiency leads to reduced EGT availability, heightened oxidative stress, and aggravated inflammation, particularly in the tissues such as intestine, liver, and lung. Moreover, OCTN1 activity is dynamically regulated by epigenetic modifications, cytokines, and hormones, linking it to immune modulation and disease progression. Put together, OCTN1 plays a defined role via high-affinity EGT transport, while its broader transport capacity and pharmacological relevance remain under investigation, with possible - though not yet established - implications for inflammation-associated biomarker development.Keywords: OCTN1, SLC22A4, Ergothioneine, Inflammation, Oxidative stress Introduction In 1997, OCTN1 was discovered as a novel gene isolated from human fetal liver, encoding a 551-amino acid protein with 12 membrane-spanning domains (including a nucleotide binding motif) that transported organic cations such as tetraethylammonium (TEA+) [1] (Fig. 1). The human OCTN1 (hOCTN1) displayed a low similarity (~ 30%) to previously characterized organic cation transporters (OCTs) in amino acid sequence, and demonstrated a saturable, ATP-dependent and pH-sensitive uptake of TEA+ through a single low-affinity binding site, possibly located at the extracellular portion between its transmembrane domains 3 and 4 [1, 2]. Interestingly, the molecular weight of hOCTN1 was measured ~ 75 kDa, substantially higher than expected from its amino acid sequence [2], suggesting a post-translational modification of this membrane-associated protein, probably glycosylation. Genomic organization and predicted protein topology of hOCTN1. A The human SLC22A4 gene is schematically shown across an approximately 49.8-kb genomic region and contains 10 exons with the indicated 5’- and 3’-untranslated regions [3]. B Predicted topology of OCTN1 showing 12 transmembrane domains, with the N- and C-termini located intracellularly. Conserved cysteine residues in the large extracellular loop, including C50, C81, C113, and C136, and others such as C236, C270, and C374, are indicated. The inset (in the dotted circle) shows the predicted three-dimensional structure of OCTN1 generated using AlphaFold and mapped onto the membrane orientation [4] Insofar, the OCTN subfamily of the solute carrier family 22 (SLC22) transporters comprises three members: OCTN1 (SLC22A4) and OCTN2 (SLC22A5), which are conserved across vertebrates including humans, and OCTN3 (SLC22A21), a less well-characterized paralog that is not present in humans but occurs in select non-human species, such as rodents and zebrafish [5]. OCTN1 shares 77% sequence identity and 88% homology with OCTN2 in humans, suggesting their common biochemical or physiological functions that allow them to share some substrates and inhibitors [6]. Since its discovery, hOCTN1 has been expressed in a variety of mammalian cells or reconstituted in engineered lipid bilayer systems (e.g., liposome, proteoliposome) to study the membrane transport property [7–9]. Consequently, several endogenous organic cations, including acetylcholine, γ-butyrobetaine, carnitine and acetylcarnitine, were then identified as the transport substrates of OCTN1, albeit varying binding affinities were reported [10, 11]. Among them, carnitine, a highly polar zwitterionic substance essential for transport of long-chain fatty acids across the inner mitochondrial membrane for their β-oxidation, was considered as the physiological substrate for both OCTN1 and OCTN2, although OCTN1 mediates the carnitine transport with a much lower affinity [6, 12]. Carnitine was transported via a Na+-dependent symport mechanism, where extracellular Na⁺ binding drives conformational changes to enable inward transport of carnitine, utilizing the Na⁺ electrochemical gradient rather than ATP hydrolysis [13, 14]. Studies adopting proteoliposome systems found out that OCTN1-mediated transports of TEA+, acetylcholine, and acetylcarnitine occur with distinct sodium sensitivity (i.e., TEA+ and acetylcholine uptake are inhibited by sodium, while acetylcarnitine transport is sodium-independent) [8]. OCTN1, originally characterized as a polyspecific transporter for organic cations and zwitterions, exhibits markedly variable transport efficiencies and likely physiological relevance across its reported substrates. The subsequent identification of ergothioneine (EGT), a diet-derived zwitterionic antioxidant, as a high-affinity substrate fundamentally redefined the functional specificity of OCTN1 [15]. This seminal work established OCTN1 as the EGT transporter (ETT), demonstrating that it mediates cellular uptake of EGT with efficiencies orders of magnitude greater than those observed for conventional substrates such as TEA+ or carnitine, thereby supporting EGT as its principal physiological substrate [16]. EGT is a naturally occurring thiol/thione compound that cannot be synthesized in humans and is instead obtained exclusively from dietary sources, particularly mushrooms, as well as certain bacteria and fungi [17]. Following absorption, EGT is widely distributed across tissues via OCTN1, where it can accumulate to high intracellular concentrations - reaching the millimolar range in certain organs - particularly those exposed to elevated oxidative stress [17]. Single nucleotide polymorphisms (SNPs) of OCTN1 The OCTN1 (SLC22A4) gene is located on a cytokine gene cluster at chromosome 5q31 locus that identifies risk haplotypes containing SNPs, which confer significant susceptibility to chronic inflammatory diseases, including inflammatory bowel diseases (IBDs) (i.e., Crohn’s disease and ulcerative colitis) [18] and rheumatoid arthritis [19]. Among them, 1672 C→T substitution in SLC22A4 exon 9 that leads to the L503F mutation, prevalently in Caucasian population, heightens development risk of IBDs and sporadic colorectal cancer in early age (< 50 years old) [20, 21]. This L503F substitution of OCTN1 has substantial impact on uptake of endogenous substrates (e.g., carnitine) due to much lessened affinity and transport efficiency, so inducing metabolic disorders as an initiation of chronic inflammatory diseases. This has been evidenced by hyperactivation of CD4+ T cells and enhanced production of pro-inflammatory cytokines, found in patients with IBDs carrying OCTN1 1672T variants or in animal models with experimental colitis [21, 22]. Similarly, in the Japanese population the SNP g1531a in the exon 9 causes G462E mutation in OCTN1 protein, nullifying its TEA+ transport activity while unaffecting the protein expression and localization. The influence of this SNP on disease susceptibility or severity has not been identified [23]. In healthy ageing individuals, rs156033 was identified as the variant showing the strongest association signal (i.e., the lead SNP) at the SLC22A4 locus, while additional variants (e.g., rs419291) in the same locus were also significantly associated with circulating carnitine and related metabolite levels [24, 25]. In parallel, OCTN1 has been reported to interact with selected cationic xenobiotics under experimental conditions; however, its contribution to the absorption, distribution, metabolism, and elimination of these compounds remains limited and incompletely established (Fig. 2). Imatinib is the first approved tyrosine kinase inhibitor (TKI) through oral administration for treatment of multiple cancers, especially chronic myeloid leukemia (CML), and SNP in the regulatory regions of imatinib transporter genes has been found in close connection with the treatment response, typified by OCTN1. Although OCTN1 exhibited a lower affinity for imatinib compared to other proteins in the OCT family [26], and this interaction may be further constrained by the comparatively low expression level of SLC22A4 relative to other SLC genes (e.g., in leukocytes SLC22A4 is significantly lower than SLC22A5) [27], patients with rs460089-GC genotype receiving first-line imatinib treatment had a higher probability of achieving a major molecular response (MMR), a molecular relapse free survival (MRFS), and an event-free survival (EFS) than patients with rs460089-GG [27, 28]. Thus, the SNP rs460089, a locus heavily influencing transcription factor binding in the SLC22A4 promoter, was found to be independent predictor of first-line imatinib treatment in patients with CML. Similarly, for patients diagnosed with CML and gastrointestinal stromal tumors, those with the presence of C allele in OCTN1 promoter (SNP rs105152-CC/CT) had better MMR and time to progression (TTP) than with SNP rs105152-TT [29, 30]. Therefore, the SNP in OCTN1 promoter region may influence its expression levels and have been associated with altered imatinib uptake in specific clinical contexts. Chemical structures of substrates transported by OCTN1 [4]. This figure depicts representative molecular structures of substrates recognized and transported by OCTN1, grouped into the following classes: A human endogenous metabolites (e.g., acetylcholine, carnitine); B fungal and plant metabolites (e.g., ergothioneine, stachydrine); and C pharmaceuticals and xenobiotics (e.g., metformin, imatinib) Clinical evidence indicated that increased OCTN1 expression was closely associated with improved overall survival (OS) and EFS in patients with acute myeloid leukemia (AML) receiving cytarabine treatment, owing to a temperature-sensitive, Na+-/pH- dependent, and saturable OCTN1-mediated cytarabine transport, where the binding site (substrate recognition site) on OCTN1 for cytarabine may differ from that for low molecular weight cations (e.g., TEA+) [31]. Furthermore, decreased cytarabine uptake was found to be closely associated with increased methylation of CpG122 island in SLC22A4 promoter that reduced the OCTN1 expression, leading to worsened outcomes of patients with AML [32]. Similarly, in the intestine and kidney, OCTN1 mediated the apical transport of gabapentin, a prescribed drug for a variety of neurological disorders (e.g., epilepsy), in an Na+-independent manner, suggesting that its renal transport took place in the secretory direction from cell to lumen [33]. This drug transport activity was largely impaired in the genetic variant of OCTN1-L503F and individuals carrying OCTN1-L503F polymorphism, giving a hint for the possible binding site of OCTN1-gabapentin interaction, although the interaction site(s) could be multiple. Differently, stably expressed OCTN1 in cancer cell lines heightened the sensitivity and cellular uptake of mitoxantrone and doxorubicin that structurally contained three or four fused rings with high aromaticity, sharing and competing with TEA+ for transport mechanism [34]. Moreover, with similar protein expression levels, OCTN1 variant L503F exhibited higher uptake activities for biguanides (including metformin, buformin, and phenformin) than wild-type OCTN1 [35]. Thereby, SNPs in OCTN1 may have significant effects on its epigenetic modification, protein expression, substrate binding affinity, and the resultant pharmacokinetics of drug substrates if applied. Also, this effect is highly substrate dependent. Substrate specificity of OCTN1 Since its discovery, OCTN1 has been long designated as a multispecific transporter with a wide array of cationic or zwitterionic substrates, until EGT was believed to be the principal substrate of OCTN1 on which its cellular uptake highly depends [15]. The sodium gradient (> 10 times more Na+ ion extracellularly than intracellularly) across the plasma membrane endows a robust driving force for EGT influx into cells and its avid retention there without comparable efflux [15, 36, 37]. Mouse OCTN1 (mOCTN1) and rat OCTN1 (rOCTN1), which share 84% and 85% amino acid identities with hOCTN1, respectively [38, 39], catalyze EGT uptake with similar affinity, efficiency and Na+ dependence [15, 36, 37]. In contrast, rOCTN2 (with 74% amino acid identity) did not exhibit any interaction with EGT at all, but EGT may be transported by hOCTN2 with a much lower affinity than hOCTN1 [12, 15, 40]. OCTN1 functions as a context-dependent transporter, whose directionality may be governed by substrate identity, pH gradients, and ionic conditions [1, 2, 9, 37]. For instance, in both human and rodent kidneys, OCTN1 is predominantly localized to the apical membrane of proximal tubular epithelial cells, whereas evidence for its basolateral expression remains inconclusive [2, 41]. Using prototypical substrates such as TEA⁺, OCTN1 exhibits Na⁺-independent and strongly pH-dependent transport, consistent with a proton/organic cation exchange mechanism [2, 9, 41]. In contrast, the basolateral uptake of TEA⁺ from the peritubular capillary into epithelial cells is primarily mediated by other organic cation transporters (e.g., OCT2) via an electrogenic process, which is independent of Na⁺ or H⁺ gradients but sensitive to membrane potential [42] (Fig. 3A). Once inside the epithelial cell, the relatively acidic tubular lumen compared with the intracellular environment establishes a favorable proton gradient that drives OCTN1-mediated efflux of TEA⁺ into the lumen, thereby contributing to the renal secretion of organic cations. This process operates in concert with other key transporters, particularly basolateral OCTs and apical multidrug and toxin extrusion proteins (MATEs), which together constitute the principal pathways for renal clearance of xenobiotics and drugs [42]. Substrate-specific transport by OCTN1. A Substrate-dependent transport of EGT and organic cations by OCTN1 in the renal proximal tubule. OCTN1 is predominantly localized to the apical membrane of proximal tubular epithelial cells, with limited evidence supporting basolateral expression. For organic cations such as TEA⁺, OCTN1 mediates Na⁺-independent, pH-dependent transport, facilitating proton-coupled efflux into the tubular lumen. Basolateral uptake of TEA⁺ from the peritubular capillary is primarily mediated by OCTs (e.g., OCT2). For EGT, OCTN1 functions as a high-affinity uptake transporter, mediating reabsorption of glomeruli-filtered EGT from the tubular lumen. This process is largely independent of Na⁺ gradients and is driven by the intrinsic substrate affinity of OCTN1, thereby minimizing urinary loss. B Schematic illustration of three OCTN1 transport systems, highlighting methodological discrepancies contributing to conflicting polyspecificity data. (i) Proteoliposome system, showing dose-dependent inhibition of organic cationic substrates (e.g., TEA+) by divalent cations (Cd²⁺ > Zn²⁺ > Pb²⁺ > Hg²⁺ > Cr²⁺), with high-affinity zwitterionic transport of EGT and carnitine. (ii) OCTN1-overexpressing in vitro system, demonstrating efficient transport of endogenous substrates (e.g., spermine). (iii) Cells that natively express OCTN1, having transport preference for substrates with betaine backbone components In contrast, OCTN1-mediated transport of zwitterionic substrates (e.g., EGT) displays distinct kinetic and regulatory features. EGT is transported by OCTN1 with exceptionally high affinity, and its uptake is characterized by Na⁺-dependence with only modest pH sensitivity [15], indicating a mechanistic divergence from classical proton-coupled organic cation exchange. In the renal proximal tubule, OCTN1 is thought to mediate the reabsorption of filtered EGT from the tubular lumen, thereby contributing to its efficient intracellular retention and systemic conservation [43]. This process appears to be driven less by luminal Na⁺ gradients and more by the intrinsic high affinity of OCTN1 for EGT, and possibly through an exchange mechanism for organic cation secretion [33]. These findings support a substrate-dependent, bidirectional functional model of OCTN1 in the kidney; that is, facilitating proton-coupled efflux of organic cations, while mediating high-affinity uptake and reabsorption of EGT to prevent its urinary loss. The common assays applied to assess the transport efficiency of OCTN1 are conducted on either cell-free or cell-based systems (Fig. 3B). Among them, proteoliposomes are constructed by mixing phospholipids with transporter proteins, through which recombinant OCTN1 can be inserted in artificial membrane bilayers, followed by detergent removal by hydrophobic resins or dialysis [10]. The main advantage of this proteoliposome model lies in the absence of other transporters in the same experimental vesicle, which may otherwise interfere with OCTN1-mediated transport process. However, compared to intact cell systems, this lack of complex protein-protein interaction is its major drawback to yield artifacts. Using this cell-free assay, two distinctive transport pathways involving different binding sites for cations and zwitterions were proposed [13]. Both organic cation (e.g., TEA+) and zwitterion (e.g., carnitine and EGT) interact with OCTN1 via E381 in competition with Na+ binding, where cation uptakes can be inhibited, but zwitterions can alternatively bind OCTN1 via R469 for cellular uptake. Via this conditional mechanism on the presence of Na+ ions, the OCTN1 binding affinity for EGT was found to be much higher than that for carnitine [13]. Additionally, exploiting this proteoliposome tool, dose-dependent inhibition of [14C]-TEA+ as the substrate was found by Cd2+> Zn2+> Pb2+> Hg2+> Cr2+ in decreasing order of potency, mostly due to the binding of heavy metal ions with cysteine residues of OCTN1 in the extracellular loop [44]. In parallel, in vitro cell systems have also been actively instrumented to evaluate OCTN1 transport activity. Typically, radiolabeled substrates are fluxed through plasma membranes of cell lines, either being transfected with OCTN1-encoding plasmids for overexpression or natively expressing OCTN1 transporter, to examine transport function. The stably overexpressing systems can greatly enhance the protein levels of OCTN1, achieving transport of substrate with better resolution. Through this method, OCTN1 was found to prefer the glycine betaine backbone in its substrates, including EGT, stachydrine (i.e., proline betaine), betonicine, proline, N-methyl proline, hydroxyproline and γ-butyryl betaine, where a fully alkylated nitrogen in the structure may render higher transport activity [36]. The transport efficiency of OCTN1 for EGT was nearly 4-fold higher than stachydrine, 25-fold higher than hercynine (EGT natural precursor), and 100-fold higher than TEA+ and carnitine, whereas this transport could be suppressed by potent inhibition of pyrilamine, quinidine and verapamil [36, 45]. Recently, spermine was reported to be the endogenous substrate of OCTN1 with comparable affinity to EGT, so maintaining the homeostasis of antioxidative spermine in the body [46]. However, in heterologous overexpression systems, particularly following transient transfection, membrane transporters may exhibit altered folding, trafficking, or membrane orientation due to the absence of native regulatory factors, which can complicate interpretation of substrate interaction data [47]. Alternatively, using endogenous OCTN1 transporters in natively expressed cells (e.g., HeLa cells), the primacy of EGT over other substrates, including TEA+, choline, acetylcholine, carnitine, acetylcarnitine, gabapentin, metformin, and particularly EGT metabolites with structural similarities (i.e., hercynine and S-methyl EGT), was confirmed, suggesting that OCTN1 has a high selectivity on EGT uptake and may contribute to trivial transport of other compounds without physiological relevancy. Besides, through this native OCTN1 system, pyrilamine, quinidine and verapamil were revealed to be efficient inhibitors against OCTN1 rather than its competitive substrates [48]. At the same time, a trimethylammonium group was believed to be a key structural determinant of OCTN1-mediated cellular uptake and intracellular activity of EGT [49]. Therefore, despite inconsistency, all experimental results agree that EGT exhibits the highest affinity for OCTN1 among known substrates, and no other transporter proteins have been so far identified in human tissues or organs that specifically interact with EGT [50, 51]. Notably, a highly selective ATP-binding cassette transporter (EgtUV) may be utilized by gastrointestinal microbes (e.g., Helicobacter pylori) for EGT uptake and redox homeostasis [52]. The transport efficiency of EGT was found to be fully maintained or even elevated by amino acid substitutions in OCTN1, but the domain 194–294 is indispensable for proper EGT binding and transporting [53, 54]. Using AlphaFold to generate the 3D structure of OCTN1 based on an experimentally solved protein structure of OCT3 with high homology, it was predicted that Y211, E381, and R469 are key substrate cognition residues, where E381 is also a putative Na+ binding site [55]. OCTN1 contains two alternative conformations when transporting EGT across the cell membrane, one open to the cytoplasm (inward-open) and the other open to the periplasm or extracellular space (outward-open) (Fig. 4). For OCTN1 protein, salt bridges at the cytoplasmic domain (i.e., R169-E220 and R397-E450) and cluster formations in the central transport pore (i.e., N210, Y211, C236, E381, and R469) may be responsible for the conformational change [56]. The transport function of EGT was completely abolished in R83P variant and largely truncated in three variants of R63H, G482D, and I500N, corresponding to four common SNPs of SLC22A4 gene in Singaporean populations [57]. As R63 and R83 seat in the large extracellular loop, G482 is near the cell membrane boundary, and I500 is located within α-helix in transmembrane domain 12, their mutations with decreased EGT uptake may reveal the dynamic process involving an array of hOCTN1 binding sites. Despite extensive research, the exact binding and transporting mechanism of OCTN1 towards EGT awaits to be elucidated. Predicted conformational dynamics of OCTN1 during EGT transport. Structural models of hOCTN1 illustrate a proposed mechanism for EGT transport across the plasma membrane. A In the predicted outward-open conformation, EGT is positioned within an extracellular-facing vestibule, where candidate pocket residues include Glu386, Arg469, Ala43, Val40, Pro143, Val481. B In the predicted inward-open conformation, EGT is positioned toward the cytoplasmic-facing vestibule, with nearby candidate residues including Gly44, Asn367, Thr45, Thr142, Cys236, Tyr211, and Asn210. The highlighted residues 194-294 region may contribute to EGT recognition and transport efficiency Recently, in OCTN1-transfected HEK293 cells or blood cells from zebrafish embryos, OCTN1 was found to have a higher affinity for selenoneine (a selenium analogue of EGT) than EGT, which could effectively transport selenoneine to reduce the intracellular methylmercury (MeHg) accumulation through formation and excretion of inorganic Hg-containing exosomes, a mission that cannot be fulfilled by EGT [58]. Otherwise, OCTN1-deficient zebrafish embryos became more lethal to MeHg exposure and less recoverable by selenoneine detoxification [58]. Incidentally, two cysteine residues in hOCTN1 (i.e., C50 and C136) were reported to be the inhibitory targets of mercury compounds [59]. This finding proposed a MeHg cleansing pathway in which selenoneine is a highly specific substrate of OCTN1 to be transported into cytosol and so formed selenoneine-MeHg complexes in response to oxidative stress are decomposed to mercury selenide (HgSe) and incorporated into extracellular vesicles through the functioning of OCTN1. It was confirmed that selenoneine due to fish intake was a major source of Se in the red blood cells of oceanside residents, essential for human health with strong antioxidant and detoxifying properties [60]. Notably, selenoneine is transported by OCTN1 only in the form of reduced monomer, acting as a reactive oxygen species (ROS) scavenger, to be oxidized and dimerized with redox stability when selenoneine diselenide is formed by linking two selones with a single methylene group [61]. Thus, OCTN1 has been implicated in the transport of selenoneine; however, its role in selenium homeostasis and redox regulation in vivo has not been definitively established. Tissue distribution and subcellular localization of OCTN1 Human OCTN1 is highly expressed in a wide array of tissues, such as kidney, lung, trachea, small intestine, cord blood, fetal liver (not in adult liver) and bone marrow, but remains nearly undetectable in certain types of cells, such as peripheral leukocytes, neutrophils, eosinophils and stem and blast cells (including early hematopoietic progenitor cells, myeloid blasts, and promyelocytes) [15]. Simultaneously, OCTN1 was highly expressed in alveolar epithelial cells and macrophages, which played a critical role in drug transport and absorption in the human lungs and intestines [62]. Albeit lower than that of OCTN2, mRNA levels of OCTN1 were detected in the human heart where OCTN1 proteins were localized in vascular structures and cardiomyocytes. The transport activity of various cardiovascular drugs by OCTN1 predicted its vital role in cardiac repair [63]. Notably, OCTN1 was functionally expressed in human corneal and conjunctival epithelial cells, suggesting its involvement in the transport of endogenous substrates in ocular tissues [64]. In rats, OCTN1 mRNA transcripts are present in a variety of tissues, principally in the liver, intestine, kidney, with a relatively lower level in the brain, thymus, lung, heart, spleen, skin and placenta, but barely detectable in skeletal muscle, stomach and testis [39]. In mice, biodistribution of EGT after oral administration indicated a similar tissue tropism, suggesting a comparable OCTN1 expression pattern to that in rats, as OCTN1 explicitly signified EGT activity [43]. Although not an hOCTN1 ortholog, an EGT transporter was discovered in zebrafish (ETTzf), as its mRNA was detected in skin, intestine, kidney, brain and eye, but not in liver, heart, muscle, spleen nor gills, where the distribution of OCTN1 was positively associated with the variety of EGT contents in different tissues after feeding [65]. OCTN1 is functionally expressed in various regions of mouse brain, including the midbrain, medulla, pons, hypothalamus and hippocampus [66]. For instance, OCTN1 was functionally expressed in rodent choroid plexus, responsible for EGT uptake, distribution into neurons, and elimination from cerebrospinal fluids after its intracerebroventricular (i.c.v) administration [67]. OCTN1 mRNA was found with the highest expression in the cerebellum, followed by medulla and pons, striatum, hippocampus, and cerebral cortex, where EGT distribution post i.c.v. injection coincided with OCTN1 expression pattern, showing significantly higher contents in the brain of wild-type rather than OCTN1−/− mice [68]. In addition, recent discovery has confirmed that OCTN1 is expressed in the mouse cochlea, where its mediated EGT transport may promote Nrf2 expression and nuclear redistribution to enhance the antioxidant capacity of cells against drug-impaired hearing loss [69]. More specifically, OCTN1 expressions have been observed in each major tissue in the cochlea, including stria vascularis, organ of Corti, and modiolus, which may utilize EGT against oxidative stress and inflammation, slowing down the progression of age-related hearing loss [70]. Nonetheless, there is yet solid evidence that validates the substantial expression of OCTN1 in the blood-brain barrier (BBB). Analyses on post-mortem specimens using quantitative targeted proteomics (QTP) verified the unquantifiable expression of OCTN1 in human brain microvascular endothelial cells (hBMEC) as the major element of BBB [71], although the cultured hBMEC [72] or BMEC derived from human induced pluripotent stem cells [73] showed weak expression of OCTN1. Thus, the outcome of EGT permeation across the BBB and accumulation in the brain points out a possibility that other transporters rather than OCTN1 may be responsible for EGT uptake and relocation, such as SLC22A15 (encoding fly-like putative transporter 1 or FLIPT1), albeit with a much lower affinity [74]. Similarly, a study using QTP on human placentas collected from different gestational ages revealed the undetectable abundance of OCTN1 expression [75], despite the finding that SLC22A4 transcripts were weakly detected in human choriocarcinoma-derived cell line BeWo and fresh villous fragments derived from human term placentas [76]. In pregnant rats, placental OCTN1 expression was found to be substantially elevated through gestation, underlining its unknown but potential role in mediating fetal growth [77]. Notably, emtricitabine, an anti-HIV drug used during pregnancy to prevent mother-to-child transmission, has been identified as a substrate of OCTN1. Experimental studies suggested that OCTN1, together with equilibrative and concentrative nucleoside transporters, may contribute to drug uptake from the maternal circulation into trophoblasts [78]. However, this process involves multiple transporters, and the specific contribution of OCTN1 is not fully defined. For epithelial polarity, OCTN1 was predominantly expressed at the apical membrane of small and large intestines, kidney, and lung, important for tissue uptake and distribution of cationic xenobiotics or drugs, and at least partially responsible for excretion of metabolic products [79]. A mutation in OCTN1 (C113Y) causing autosomal recessive deafness in North African populations was found to be associated with its lower abundance than the wild type at the apical plasma membrane in cochlear endothelial cells, so affecting the trafficking of the transporter and weakening EGT uptake [80]. This is consistent with a previous report that mutations in OCTN1 may substantially alter its subcellular localization from plasma membrane to cytoplasm [54]. Also, study on rodent models discovered that OCTN1, absorbing food-derived EGT, was localized on the intestinal apical cellular membrane, where the postsynaptic density 95/disk-large/ZO1 (PDZ) binding motif at the C-terminus of OCTN1 could interact with PDZ domain containing protein PDZK1 to sustain its position [81]. Compromised expressions or mutations of PDZK1 as the scaffold protein may disrupt OCTN1 localization on the apical cell membrane, triggering OCTN1 trafficking into cytoplasm and diminishing EGT transport across the epithelial sheet [81, 82]. In addition, microtubule-associated protein 2 (MAP2) as a crucial neuronal cytoskeletal regulator and βIII-tubulin (neuron-specific isoform of tubulin) were partially colocalized with OCTN1 in the mouse brain, albeit no protein interactions between them were detected [68]. OCTN1 has been detected in mitochondria-associated compartments, raising the possibility of proximity to the outer mitochondrial membrane, although definitive sub-mitochondrial localization remains unresolved [83–85]. EGT can be internalized into isolated mitochondria, much faster than the cellular uptake, implying higher expression levels of OCTN1 and existence of other unknown transporters on mitochondrial membranes [86]. Recent findings disclosed that transcriptional co-activator PGC-1α is induced upon exercise training of mice, further upregulating the expression of SLC22A4 that encodes OCTN1 to increase the uptake of EGT. Consequently, EGT directly binds to and activates the mitochondrial 3-mercaptopyruvate sulfurtransferase (MPST) to enhance mitochondrial respiration [87]. Although this study revealed this direct EGT-MPST binding in situ and did not confirm the intra-mitochondrial availability of EGT, it might partially explain the earlier findings that cells with OCTN1 depletion were more vulnerable to mitochondrial DNA damage, protein oxidation and lipid peroxidation [88] (Fig. 5). Tissue distribution and subcellular localization of OCTN1 across species. This figure illustrates OCTN1 (SLC22A4) expression patterns, with different colors indicating the varying levels. A High human OCTN1 expression in kidney, lung, trachea, small intestine, cord blood, fetal liver, and bone marrow, but low or undetectable levels in peripheral leukocytes, neutrophils, eosinophils, and stem/blast cells. B Similar rodent (rat/mouse) distribution, with prominent expression in liver, intestine, and kidney; moderate levels in brain, thymus, lung, heart, spleen, skin, and placenta; and low or undetectable levels in skeletal muscle, stomach, and testis, correlating with EGT biodistribution. C Subcellular apical membrane localization in polarized epithelia (e.g., intestine, kidney, lung), stabilized by PDZK1 (postsynaptic density-95/disk-large/ZO-1-binding protein 1), and mitochondrial proximity enhancing SLC22A4 expression via PGC-1α (peroxisome proliferator-activated receptor gamma coactivator-1 alpha) upregulation, boosting OCTN1 expression and EGT uptake, with EGT directly binding MPST (3-mercaptopyruvate sulfurtransferase) in mitochondria Alternatively, a study on subcellular distribution of EGT in hepatic cells 10 min after its intraperitoneal administration in rats revealed that 65% of injected EGT was found in cytoplasm, followed by mitochondria and microsomes with similar contents (~ 15%), and a trace amount in the nucleus (~ 3%) [89]. Intriguingly, this distribution barely decreased within two weeks following injection, even with increasing accumulation in mitochondria, which showed the stability of EGT after intracellular internalization and mitochondrial uptake. In mdx mice as a model for carnitine deficiency in Duchenne muscular dystrophy (DMD), the mRNA expression of mitochondrial OCTN1 was upregulated in quadriceps compared to the control, illustrating a bioenergetic compensation machinery; however, OCTN1 protein expression remained comparable, proposing that the oxidative stress in DMD imposed peroxidative damage on mitochondrial membrane, then degrading OCTN1 [90]. These findings support a defined role for OCTN1 as the primary high-affinity transporter for EGT at the cellular level, while its distribution across specific subcellular membranes remains unresolved. In addition, accumulation of EGT in the nuclei of human skin cells (including neonatal normal human dermal fibroblasts and neonatal normal human epidermal keratinocytes) was shown in a similar magnitude to that in the cytoplasm [91]. However, whether OCTN1 exists as a soluble cytosolic protein or is confined to membrane-associated compartments has not been established. Current evidence supports that OCTN1 is predominantly localized to the plasma membrane where it mediates cellular uptake of substrates. There is no definitive evidence demonstrating its localization to the nuclear membrane. Any observed nuclear accumulation or nuclear effects of OCTN1 substrates are more likely mediated indirectly following cytosolic uptake, rather than through direct nuclear transport by OCTN1. The phenotype of OCTN1 knockout animal models The use of OCTN1-deficient animal models has been instrumental in understanding the pathophysiological role of this protein. The OCTN1 gene knockout (OCTN1−/−) mice were first developed in 2010, where EGT became undetectable in various tissues (e.g., liver, intestine, kidney), plasma and urine in sharp contrast with micromolar to millimolar levels in wild-type mice. This OCTN1 depletion resulted in higher susceptibility to intestinal inflammation, oxidative stress, and mortality after gut ischemia-reperfusion [43]. These findings corroborate a central role of OCTN1 in maintaining EGT homeostasis through intestinal absorption, hepatic uptake and renal reabsorption. In OCTN1−/− mice, lowered but standing uptake of EGT in intestinal, renal and hepatic tissues afforded an increased plasma level of EGT after oral absorption, inferring that hepatic uptake of EGT in wild-type mice is rate-limited by the blood flow and alternative transporters in vivo other than OCTN1 are accountable for EGT uptake in OCTN1−/− mice [92]. However, the minimal difference in the phenotypes between wild-type and OCTN1−/− mice makes it demanding to understand the exact physiological role of OCTN1. Further study on dextran sodium sulfate (DSS) induced colitis mice revealed the increased OCTN1 expression and EGT absorption in inflamed small intestine and colon, where infiltrated macrophages internalizing EGT were recruited. Compared to wild-type, OCTN1−/− mice exhibited exacerbated DSS-induced colitis, including accelerated body weight loss, shortened colon length, and heightened inflammation severity, which confirmed a beneficial role of OCTN1 in intestinal inflammation by mediating EGT uptake [93]. Consequently, DSS-induced colitis led to a substantial dysbiosis, marked by decreased richness and evenness of gut microbiota, which became even worse and less sensitive to anti-TNF-α therapy in OCTN1−/− mice [94]. Compared to mucosal T cells in the healthy controls, DSS-induced colitis nearly unaffected memory and naïve T lymphocytes but increased Treg and T-helper subpopulations in the wild-type mice, while this experimental colitis lowered Treg, memory T, and Th17, but increased naïve T, Th1 and Th2 subtypes in OCTN1−/− mice [94]. Therefore, immune cell population and inflammatory response in the mucosal immunity are distinctly altered in the OCTN1-deficient mice. Similarly, in the experimental liver fibrosis mice, more activated hepatic stellate cells and Kupffer cells were detected in the liver where the fibrosis degree and oxidative stress became more severe in OCTN1−/− than wild-type mice [95]. Exacerbated renal fibrosis and kidney injury were also observed in OCTN1−/− mice with chronic kidney disease (CKD) [81]. Likewise, in the mouse model of type 1 diabetes, oxidative stress in the kidney was elevated in OCTN1−/− mice compared to wild-type controls. Correspondingly, cytoskeleton- and cell adhesion-related pathways were upregulated (represented by moesin), whereas oxidative phosphorylation- and intracellular transport-related pathways were downregulated in OCTN1−/− mice of diabetic nephropathy when compared to wild-type controls, leading to worsened progression of interstitial inflammation and fibrosis [96]. Irrespective of EGT uptake, OCTN1 may promote neuronal differentiation and suppress neuronal proliferation by upregulating GAP43 and downregulating SOX2 and HO-1, indicating its regulatory function under cellular oxidative stress [68]. Additionally, in rat neurons, OCTN1 takes a major responsibility for mediating neuronal uptake and neurotoxicity of oxaliplatin, with a lesser contribution from OCTN2 and OCT. Depending on temperature and sodium concentration, this mediation can be competitively inhibited by EGT, making OCTN1 a pharmaceutical target when the dose-limiting toxicity needs to be attenuated [97]. In mice challenged with 6-hydroxydopamine (a parkinsonian neurotoxin injected into the unilateral striatum to ablate dopaminergic neurons), EGT treatment via oral administration ameliorated their behavioral deficits, but these benefits were ablated in OCTN1−/− mice, demonstrating a neuroprotective effect of EGT in preventing or treating Parkinson’s disease [98]. Lipopolysaccharide (LPS) stimulated cellular hypertrophy through generation of ROS, identified by increases in the number of large cell bodies and the area and perimeter of cells, was much mitigated but the induction of pro-inflammatory interleukin IL-1β mRNA was aggravated in OCTN1−/− microglia compared to wild-type one [99]. EGT promoted neuronal differentiation of neural stem cells derived from wild-type mice but not those from OCTN1−/− mice [100]. However, whether the internalized EGT or OCTN1 per se is responsible for neuronal differentiation remains undetermined, since knockout of OCTN1 simultaneously diminishes intracellular content of EGT. In mouse neural stem cell line NE-4 C, EGT was internalized into cells to provoke the Ca2+ release from the endoplasmic reticulum via inositol 1,4,5-triphosphate receptor (IP3R) channel, further increasing the brain-derived neurotrophic factor (BDNF) and phosphorylated cAMP response element-binding protein (CREB) expressions, so to stimulate nerve transmission [49]. Conversely, pyrilamine, an OCTN1 antagonist, inhibited Ca2+-CREB/BDNF activation, suggesting a modulating role of internalized EGT instead of membrane transporter-mediated signaling pathway. However, in wild-type mice intraperitoneally injected with pentylenetetrazole (PTZ) to induce epileptic seizure, the neuronal excitation marker genes c-fos and Arc, and BDNF were upregulated in the hippocampus, a process further deteriorated by OCTN1-mediated uptake of food-derived homostachydrine. Oppositely, OCTN1 deletion mitigated the PTZ-induced seizures by restricting homostachydrine transport and suppressing the epilepsy-promoting genes in the brain, therefore lowering the seizure severity and improving the survival rate in OCTN1−/− mice [101]. Knockouts of OCTN1 have been successfully generated in non-rodent organisms, providing valuable insights into its conserved physiological functions across species. Compared to the wild-type, ETTzf−/− homozygous fish exhibited no differences in morphology, behavior or tissue histology, where EGT content was 1000 times less and 8-oxoguanine indicative of oxidative damage was 3.8 times higher [65]. In fact, mammalian SLC22A4 shows close sequence similarity with both SLC22A4 and SLC22A5 in zebrafish, whereas zebrafish SLC22A5 (not SLC22A4) is the functional ortholog of SLC22A4 in mammals [102]. Additionally, an EGT transporter analogous to hOCTN1 was identified in the nematode Caenorhabditis elegans (C. elegans) and its deletion resulted in significantly shorter lifespan, greater oxidative damage, and higher susceptibility to oxidative challenge [103]. However, the EGT intake by wild-type or knockout nematode demonstrated no substantial difference, indicating the existence of alternative pathways to transport EGT in the worm. Therefore, OCTN1 serves as an important regulator of intracellular antioxidant and anti-inflammatory capacity, primarily by controlling the bioavailability of physiological substrates (e.g., EGT), thereby influencing susceptibility to oxidative stress and inflammation across multiple organ systems. While compensatory mechanisms may obscure its role under physiological conditions, OCTN1 becomes critically important in pathological settings, where its deficiency is consistently associated with exacerbated oxidative injury and inflammatory insults, dysregulated immune responses, and worsened disease outcomes. Regulation of OCTN1 expression The SLC22A4 gene expression in humans has been reported to be positively associated with disease susceptibility and/or severity in a variety of chronic and acute inflammatory illnesses, including Kawasaki disease [104], ischemic stroke [105, 106], pediatric sepsis [107], proposing it as a diagnostic biomarker or druggable target. In parallel, SNPs in the SLC22A4 gene demonstrate strong association with many an autoimmune disease, such as rheumatoid arthritis [108], Crohn’s disease [109], and type I diabetes [110]. All these results suggest that OCTN1 is not only a transporter but also a potential modulator of inflammatory processes. In both humans and mice, OCTN1 was expressed in CD34+ hematopoietic progenitor cells and CD71+ nucleated erythrocyte progenitor cells from bone marrow and cord blood. Intriguingly, it showed strong expression in myeloid cells but not in lymphoid cells, where peripheral mature erythrocytes exhibited higher expression than immature erythrocytes, indicating a selective expression of OCTN1 during myeloid lineage commitment and its upregulation during erythroid differentiation [15, 111]. High OCTN1 levels in CD14+ monocytes/macrophages were also identified [112], while differentiation of monocytes into macrophages did not substantially change SLC22A4 expression [62, 93]. This is consistent with the finding that EGT was accumulated in human red blood cells (RBCs) and CD14+ monocytes but not in CD4+/CD8+ T cells with undetectable OCTN1 expression [113]. This may partially explain why hOCTN1 is expressed in bone marrow and fetal liver but not adult liver. Conversely, the OCTN1 knockdown in human hematopoietic cells impaired their EGT uptake, cell proliferation and erythroid differentiation, thereby reiterating a question whether those changes are specifically made by lessened OCTN1 expression or reduced intracellular accumulation of its transported compounds, such as EGT [114]. As two major branches of hematopoietic cells, the myeloid and lymphoid lineage commitment is driven by a complex interplay of intrinsic and extrinsic determinants, including cytokines, growth factors, and microenvironmental influences (e.g., oxidative stress, metabolic homeostasis), whereas disruptions in any factors may result in hematopoietic disorders, such as leukemia, anemia, and autoimmune diseases [115, 116]. Consequently, erythroid differentiation is characterized by a diversity of cellular events, including production of ROS, regulation of pro-inflammatory cytokine signaling, and modulation of transcription factors [117–119], all tuning OCTN1 expression through myeloid lineage skewing and erythropoiesis. Similarly, OCTN1 expression can be manipulated by those factors under pathological circumstances like hematological disorders and pharmacological treatments. For instance, in primary erythroid cells extracted from patients with sickle cell disease, OCTN1 expression was enhanced by its substrate hydroxyurea through transcriptional controls, to induce γ-globin expression and the ensuing increase in fetal hemoglobin production [120]. Notably, hydroxyurea-induced OCTN1 expression exhibits a sustained and positive correlation with γ-globin levels, suggesting that OCTN1 may play a functional role in mediating hydroxyurea efficacy, potentially by enhancing intracellular drug availability or participating in downstream regulatory pathways governing γ-globin transcription. In the peripheral blood collected from patients with chronic polycythemia vera (PV) who received no prior treatment, OCTN1 was expressed much higher in their hematopoietic stem/multipotent progenitor cells (HSC/MPPs) than more committed erythroid progenitors (i.e., common myeloid/megakaryocyte-erythrocyte progenitors, CMP/MEPs), as OCTN1 expression was positively correlated with hematocrit levels. Simultaneously, there was a significantly increased level of OCTN1 in patients with chronic polycythemia vera (PV) when compared to those treated by hydroxyurea in the same patient group or those physically healthy controls [121]. Thus, transcriptional controls that include epigenetic modifications (e.g., DNA methylation), signaling pathways (e.g., transcription factors, cytokine networks, and oxidative stress), and post-transcriptional regulations (e.g., miRNA binding) may govern OCTN1 expression under a variety of pathophysiological conditions. Noteworthily, OCTN1 might lose glycosylation when erythrocytes come into maturation in peripheral blood [111]. Several haplotypes of OCTN1 promoter have shown reduced transcriptional activities by a degree of 22.9%-44.6% [122]. In parallel, the basal methylation within CpG122 island of the SLC22A4 promoter region has been reported to significantly suppress the downstream transcription (39.1-fold) [32]. Those genetic or epigenetic changes may disrupt the binding of specific transcription factors that regulate SLC22A4, including nuclear factor-Y (NF-Y), NF-κB, Runt-related transcription factor 1 (RUNX1), and specificity protein 1 (Sp1), and others crucial for basal transcriptional regulation, so repressing OCTN1 transcription (Fig. 6A) [122, 123]. For example, in a cholesterol-fed guinea pig model of non-alcoholic fatty liver disease (NAFLD), a significant increase in RUNX1 mRNA was observed to induce OCTN1 mRNA expression [124]. Consistently, upon dietary intake bile acids are secreted into the lumen of small intestines, suppressing the intestinal OCTN1 expression that was activated by peroxisome proliferator-activated receptor-α (PPARα) through its binding to PPAR response elements (PPREs) in the SLC22A4 promoter [125]. Through diet supplements strong PPARα agonists (e.g., clofibrate, hydroxy and hydroperoxy fatty acids) caused a substantial upregulation of OCTN1 in the rat liver [126–128]. OCTN1 regulation in intestinal and pulmonary inflammation: homeostasis vs. pathology. This figure contrasts OCTN1 (SLC22A4) regulation in intestine and lung under normal vs. infected/injured conditions. A In intestine, infection boosts CpG122 methylation and disrupts NF-Y/RUNX1/NF-κB/Sp1 binding, suppressing OCTN1, while PPARα enhances it under normal conditions. B In lung, bacterial products/ROS trigger TLR4/MyD88/NF-κB (TNF-α/IL-1β/IL-6) inflammation, causing oxidative stress (marked by SOD/GSH/MDA changes), DNA damage, PDZK1 instability, and RUNX1-mediated SLC22A4 repression, impairing EGT transport. NF-Y, nuclear factor-Y; RUNX1, Runt-related transcription factor 1; NF-ĸB, nuclear factor kappa B; Sp1, specificity protein 1; PPARa, peroxisome proliferator-activated receptor alpha; TLR4, Toll-like receptor 4; MyD88, myeloid differentiation primary response 88; TNF-α, tumor necrosis factor alpha; IL-1β, interleukin-1 beta; IL-6 interleukin-6; SOD, superoxide dismutase; GSH, glutathione; MDA, malondialdehyde Moreover, the level of SLC22A4 mRNA can be substantially affected by inflammatory cytokine stimulation and redox or acid-base status. The upregulation of OCTN1 by pro-inflammatory IL-1β and TNF-α via NF-κB signaling cascade has been identified in several human and rodent tissues, including synovium and renal epithelium [19, 123, 129, 130]. Specifically, TNF-α upregulated OCTN1 transcription via TNF-receptor 1 (TNFR1) activation [112]. However, different from TNF-α, TGF-β might not directly participate in OCTN1 regulation [95]. Similarly, OCTN1 mRNA expression was increased in the injured tissues where ROS is a critical factor in disease initiation and progression, such as kidney disorders [81, 131]. Exposure to the bacterial endotoxin LPS modulates OCTN1 expression across multiple inflammatory contexts. LPS can be recognized by Toll-like receptor 4 (TLR4) on the surface of airway epithelial cells to initiate a signaling cascade to activate the transcription factor NF-κB, inducing various pro-inflammatory cytokines/chemokines and producing excessive ROS (Fig. 6B) [132]. In THP-1 macrophage-like cells, LPS stimulation increased TNF-α production, which was associated with elevated OCTN1 gene expression, consistent with its upregulation observed in murine colitis models [93]. Similarly, in human bronchial epithelial cells, LPS-induced inflammatory activation was accompanied by enhanced OCTN1 mRNA and protein levels, contributing to increased salbutamol transport [133]. In microglial systems, LPS elicited a time- and dose-dependent induction of OCTN1 expression alongside ROS generation, cell hypertrophy and pro-inflammatory cytokine release (e.g., IL-1β and TNF-α). Noteworthily, OCTN1 knockdown did not alter TNF-α expression but augmented IL-1β mRNA levels, suggesting a potential feedback role of OCTN1 in restraining IL-1β-mediated inflammatory responses [99]. However, contradictory findings on the downregulation of OCTN1 expression by LPS stimulation have been also reported. In lactating rats, systemic LPS exposure following intraperitoneal injection significantly reduced OCTN1 mRNA levels in the mammary gland [134]. In rat lung tissues subjected to LPS and cigarette smoke, elevated pro-inflammatory cytokines were accompanied by marked decreases in OCTN1 expression, which could be reversed by anti-inflammatory treatments such as ipratropium bromide or dexamethasone [135]. Consistently, in A549 cells, combined LPS and cigarette smoke extract exerted a synergistic effect, enhancing inflammation while further suppressing OCTN1 expression via mechanisms involving NF-κB signaling [135]. Moreover, LPS alone elevated inflammation but inhibited OCTN1 mRNA and protein expression as well as its transport activity in A549 cells, potentially through interactions with a range of genes, such as neuromedin B, PDZ domain containing 3, RASD family member 2, and calpain 2, to further reduce the distribution and disposition of drug substrate [136]. Both bacterial and viral mimetics can trigger inflammatory responses that alter OCTN1 expression. Infection with Citrobacter rodentium consistently reduced hepatic SLC22A4 expression across mouse strains, including TLR4- and IL-6-null models, whereas this effect was abolished in IFN-γ-null mice, suggesting an indispensable role for downstream cytokines such as TNF-α [137]. Notably, this regulation appears strain-dependent. Similarly, viral mimicry using polyinosinic: polycytidylic acid (poly I: C) induced pro-inflammatory cytokines (e.g., IL-6, TNF-α) and downregulated OCTN1 expression in the kidney, likely via TLR3-NF-κB signaling [138, 139]. This effect parallels endotoxin-induced inflammation [140] and may vary depending on viral type and host background (e.g., mouse strain) [63]. To summarize, inflammatory stimuli regulate OCTN1 expression in a context-dependent manner across experimental settings. These apparently divergent findings may be reconciled within a unified framework in which OCTN1 functions as a stress-responsive transporter dynamically tuned by the inflammatory microenvironment. During moderate or early-stage inflammation, activation of NF-κB and redox-sensitive pathways may upregulate OCTN1 expression as an adaptive response, enhancing cellular uptake of protective substrates (e.g., EGT) so to limit oxidative and inflammatory injury. In contrast, under sustained, excessive, or complex inflammatory conditions, often accompanied by additional stressors such as metabolic burden or systemic infection, OCTN1 expression and function are substantially suppressed, likely reflecting cellular dysfunction, reprogrammed transcriptional networks, or cytokine-mediated inhibitory signaling. Together, these findings support a model in which OCTN1 acts as a context-sensitive regulator of the inflammatory-oxidative microenvironment, reflecting a dynamic balance between protective adaptation and pathological impairment, and providing a mechanistic view for its bidirectional regulation and potential as a therapeutic target. Thus, newly added in the classic inflammation context is that the injured, infected or inflamed epithelium may alter the expression and activity of xenobiotic transporters that include OCTN1, and consequently modify drug metabolism and disposition, which would be attributable to inter-individual variations in drug response. In fact, inter-individual differences in mRNA expression of OCTN1 among blood samples drawn from only 10 healthy subjects reached a factor of 300 [113], predicting a wide range of sensitivity to potential medication and a great degree of pharmacokinetic differences for xenobiotic substrates of OCTN1 between individuals. Conversely, further medication or usage of bioactive substrates may change the expression and activity of OCTN1, exemplified as herb extract [141], EGT [33, 142], hydroxyurea [120], and antileukemic reagent SIAIS562055 [143], which all enhanced OCTN1 expression. Lastly, post-transcriptional modifications, including hormonal regulation and microRNA modulation, also influence OCTN1 expression. Its mRNA levels may vary with tissue, age, and sex, contributing to differences in xenobiotic transport [144]. OCTN1 expression tends to decline with aging and has been associated with reduced EGT accumulation and age-related disorders (e.g., cognitive impairment) [145]. In contrast, testosterone upregulates OCTN1 expression, contributing to sex-dependent differences in EGT distribution and related physiological or pathological outcomes (e.g., tooth loss and adiposity) [146, 147]. Additionally, microRNAs such as miR-137c may regulate OCTN1, promoting EGT transport and its antioxidative and anti-inflammatory functions, particularly in neurodegenerative contexts [148, 149]. Conclusions and perspectives Although OCTN1 is best known for its high-affinity transport of EGT, mounting evidence suggests that its biological relevance and importance extend beyond a transporter of a single antioxidant/anti-inflammatory substrate. Through reported interactions with selected endogenous or exogenous compounds, it safeguards against oxidative stress while influencing immune balance and metabolic homeostasis. Genetic variants and regulatory mechanisms profoundly shape OCTN1 function, linking it to variability in drug response and susceptibility to inflammatory disorders and cancer. Moreover, OCTN1 expressions are dynamically regulated by cytokines, oxidative stress, and metabolic cues, suggesting that its abundance may reflect the inflammatory microenvironment rather than merely substrate availability. Therefore, OCTN1 integrates genetic variability, tissue-specific expression, and inflammation-responsive regulation, positioning it as a potential indicator or modifier of inflammatory status. These findings highlight OCTN1 not only as a key determinant of therapeutic efficacy and disease progression but also as a promising biomarker and possible therapeutic target. Future studies integrating transcriptomics, proteomics, genomics, and patient stratification are warranted to validate OCTN1 as a clinically actionable biomarker and to clarify whether its modulation reflects compensatory protection or pathological dysregulation during inflammation and oxidative stress. Acknowledgements We are grateful for the financial support from Jiangsu University. Authors’ contributions YG, KZ and JZ wrote the draft of the manuscript and prepared figures and tables. ZT conceived the idea of this review and supervised the writing and submission of the manuscript. Funding This study was supported by Jiangsu Province Elderly Health Research Project (LKZ2024012) and Jiangsu Provincial Science and Technology Development Plan for Traditional Chinese Medicine (MS2022148). Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Yumeng Guo and Kaijian Zhou contributed equally to this work. Contributor Information Jianguo Zhang, Email: 1000011431@ujs.edu.cn. Zhimin Tao, Email: jsutao@ujs.edu.cn. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.